25105094
2014 Jul 24
Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhibitor, sunitinib. We report the first case of retinal tear possibly associated with sorafenib.
VEGFR inhibitor; angiogenesis inhibitor; hepatocellular carcinoma; retinal tear; sorafenib.
